AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Liminatus Pharma Stock Soars 14.49% on 10K Filing
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jul 2, 2025 5:50 am ET1min read
Liminatus Pharma's stock surged 14.49% in pre-market trading on July 2, 2025, marking a significant rise that has caught the attention of investors and analysts alike.
Liminatus Pharma has recently filed its 10K form with the Securities and Exchange Commission (SEC), providing a comprehensive overview of the company's financial performance and operational activities. This filing is crucial for investors as it offers insights into the company's health and future prospects.
The company's stock is actively traded on the NASDAQ, with real-time bid and ask information available to investors. The bid-ask spread is an important indicator of a stock's liquidity, reflecting the ease with which shares can be bought or sold. A smaller spread suggests higher liquidity, while a larger spread indicates lower liquidity. This information is powered by Nasdaq Basic, a premier market data solution, and is updated every three seconds to provide real-time monitoring of prices.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet